A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy

Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers

Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed

Data from new clinical trials reported positive results of radioligand therapy over everolimus and sunitinib, and explore the combination of everolimus and somatostatin analogues

Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate

The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer

Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function

Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients

Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology

However, the future of TKI combinations for these rare tumours is uncertain